Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
BACKGROUND
Patients with relapsed or refractory CD30-positive lymphoproliferative disorders such as Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) commonly have a poor prognosis. Patients with these histologies who subsequently progress after salvage chemotherapy and autologous stem cell transplantation (ASCT) have very limited treatment options and are in need of novel effective therapies.


METHODS
Based on the published literature and available abstracts, this review describes the development of a CD30-directed antibody-drug conjugate, brentuximab vedotin (SGN-35), the preclinical activity of this agent in models of HL and ALCL, as well as the results of initial clinical trials.


RESULTS
This review discusses the utility of using CD30 to target delivery of an antimitotic agent, the safety and activity of this approach, as well as potential future prospects and challenges in integrating this therapy into current treatment combinations.


CONCLUSIONS
In reviewing the initial results with brentuximab vedotin in relapsed HL and ALCL, brentuximab vedotin appears to be well tolerated and to have promising activity in CD30(+) lymphomas.
Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA. ansell.stephen@mayo.edu
Stephen M
SM
Ansell
D000818:Animals; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000276:immunology; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D011379:Prognosis
D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin